Sensei Biotherapeutics Appoints Jessie M. English, Ph.D. to its Board of Directors - Seite 2
About Sensei Biotherapeutics
Sensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation immunotherapies for the treatment of cancer and infectious
diseases. The company has developed a proprietary bacteriophage-based platform, ImmunoPhage, that enables the rapid generation of immune activating therapeutic agents that fully engage the immune
system. Using the ImmunoPhage platform, Sensei is developing a library of ImmunoPhage, called Phortress, to target multiple tumor-associated antigens to create a personalized yet off-the-shelf
cocktail approach for treating cancer patients. The platform enables efficient, scalable and cost-effective manufacturing to support all of Sensei’s clinical programs. The company’s most advanced
immunotherapy, SNS-301, a first-in-class ImmunoPhage targeting the tumor antigen Aspartyl beta Hydroxylase (ASPH), is currently in a Phase 1/2 clinical trial in patients with advanced Squamous Cell
Carcinoma of the Head and Neck. Earlier stage programs include SNS-401, an ImmunoPhage cocktail for the treatment of Merkel Cell Carcinoma, and SNS-VISTA, an antibody-based therapeutic targeting an
immune checkpoint gene that inhibits anti-tumor immune responses called V-domain Ig suppressor of T cell activation (VISTA). For more information, please visit www.senseibio.com, and
follow us on Twitter @SenseiBio and on LinkedIn.
Lesen Sie auch
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Sensei’s current beliefs and
expectations. These forward-looking statements include expectations regarding the potential clinical development of Sensei’s product candidates and the advancement and potential benefits of
ImmunoPhage. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause
actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Sensei’s reliance on third parties over which it may not always have full control, and other
risks and uncertainties that are described in Sensei’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 30, 2021 and Sensei’s other Periodic Reports
filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Sensei as of the date of this release, and Sensei
assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.